25,082 Shares in Charles River Laboratories International, Inc. $CRL Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 25,082 shares of the medical research company’s stock, valued at approximately $7,399,000.

Other hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its stake in shares of Charles River Laboratories International by 127.9% during the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after buying an additional 55 shares during the period. Continuum Advisory LLC purchased a new stake in shares of Charles River Laboratories International during the second quarter valued at $30,000. IFP Advisors Inc increased its position in shares of Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 106 shares during the period. Compass Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $69,000. Finally, Activest Wealth Management raised its stake in Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after acquiring an additional 57 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 7.2%

NYSE CRL opened at $326.62 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company has a market capitalization of $15.59 billion, a PE ratio of -67.34, a P/E/G ratio of 3.29 and a beta of 1.36. The company has a fifty day moving average of $304.55 and a 200 day moving average of $224.12.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.12. The company had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period last year, the firm earned $2.43 EPS. Research analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on CRL shares. Mizuho lifted their price target on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Evercore set a $330.00 price objective on Charles River Laboratories International in a report on Friday, September 25th. Robert W. Baird raised their price objective on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Argus set a $330.00 target price on Charles River Laboratories International in a report on Thursday, September 17th. Finally, Barclays upped their target price on Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $302.33.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Third-quarter adjusted earnings were $3.09 per share, above estimates of about $2.97, and revenue of $982.7 million beat expectations of roughly $960.4 million. Organic growth and margin expansion supported results, and the company lifted its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
• Negative Sentiment: Despite beating estimates, revenue was down 2.2% from the same quarter last year, a possible concern for investors weighing the strong quarterly beat. Charles River Laboratories Announces Third-Quarter 2026 Results
• Negative Sentiment: Zacks Research lowered its rating on CRL from “strong-buy” to “hold,” which may have added pressure. The available reports note that shares fell despite the earnings beat and raised outlook, but do not give a definitive explanation for the market reaction. Zacks Research rating information

Insider Buying and Selling

In related news, Director James C. Foster sold 24,042 shares of the firm’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $11,058,600. This trade represents a 43.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 102,299 shares of company stock worth $31,050,863 over the last ninety days. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.